About: The National Vaccine Advisory Committee at 30: Impact and opportunity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The National Vaccine Advisory Committee at 30: Impact and opportunity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The National Vaccine Advisory Committee at 30: Impact and opportunity
Creator	Gellin, Bruce Hinman, Alan Orenstein, Walter Thompson, Kimberly
Source	Elsevier; Medline; PMC
abstract	Abstract Thirty years after passage of legislation that created the National Vaccine Advisory Committee (NVAC) “to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines,” this review reflects NVAC’s role and impact on the U.S. vaccine and immunization enterprise as an external advisor to the Department of Health and Human Services. We reviewed the history of NVAC in the context of the principles of its establishment, with a focus on its reports and recommendations. We performed a systematic literature review to identify NVAC reports published in widely-accessible public health journals, and we reviewed the available archives to identify other reports and resolutions approved by the committee not published in journals. We characterized key issues considered by NVAC according to the five goals of the 2010 National Vaccine Plan. The predominance of NVAC activities to date related to the implementation of immunization across the lifespan and the many aspects of the system needed to foster the goal of full immunization. Reflecting on the impacts of NVAC to date, this review identified 30 NVAC approved reports published in journals, 22 stand-alone resolutions, and 26 unique unpublished reports. The development of new and improved vaccines continues to represent a significant priority for NVAC, and we identified several challenges related to future vaccine innovation. Given the many factors that impact on policy changes in the vaccine and immunization enterprise, we encountered challenges associated with demonstrating attribution of specific policy changes to NVAC recommendations. Although difficult to quantify, this review suggests that NVAC played an important role in the improvements in the U.S. immunization enterprise over the past 30 years and that NVAC can and will continue to play an important role supporting U.S. immunization going forward.
has issue date	2018-03-07(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2018.01.068
bibo:pmid	29422369
has license	els-covid
sha1sum (hex)	91531177c812eedf1e965f086c510c6e603250ce
schema:url	https://doi.org/10.1016/j.vaccine.2018.01.068
resource representing a document's title	The National Vaccine Advisory Committee at 30: Impact and opportunity
has PubMed Central identifier	PMC7115546
has PubMed identifier	29422369
schema:publication	Vaccine
resource representing a document's body	covid:91531177c812eedf1e965f086c510c6e603250ce#body_text
is schema:about of	named entity 'full' named entity 'National' named entity 'infectious diseases' named entity 'vaccine' named entity 'foster' named entity 'reflects' named entity 'system' named entity 'enterprise' named entity 'FORWARD' named entity 'PLAYED' named entity 'QUANTIFY' named entity 'DEVELOPMENT' named entity 'CHARACTERIZED' named entity 'TO IDENTIFY' named entity 'UNIQUE' named entity 'PREVENTION OF' named entity 'OPTIMAL' named entity 'NEW' named entity 'ENTERPRISE' named entity 'PASSAGE' named entity 'IMPORTANT' named entity 'ARCHIVES' named entity 'FOCUS' named entity 'ADVISORY COMMITTEE' named entity 'HUMAN' named entity 'ITS' named entity 'PUBLIC HEALTH' named entity 'SUPPORTING' named entity 'ACTIVITIES' named entity 'REVIEWED' named entity 'REVIEW' named entity 'PERFORMED' named entity 'IMPACT' named entity 'PREVENTION' named entity 'PLAN' named entity 'INNOVATION' named entity 'ACROSS' named entity 'RECOMMENDATIONS' named entity 'VACCINE' named entity 'REFLECTS' named entity 'NEEDED' named entity 'ASSOCIATED WITH' named entity 'PUBLISHED' named entity 'JOURNALS' named entity 'THIRTY' named entity 'SYSTEM' named entity 'GIVEN' named entity 'CONTINUE' named entity 'GOAL' named entity 'ROLE' named entity 'FOSTER' named entity 'RELATED' named entity 'CHANGES' named entity 'IDENTIFIED' named entity 'HISTORY OF' named entity 'IMPLEMENTATION' named entity 'YEARS' named entity 'IMPROVED' named entity 'AVAILABLE' named entity 'APPROVED BY' named entity 'REPORTS' named entity 'U.S.' named entity 'CHALLENGES' named entity 'REPRESENT' named entity 'CONSIDERED' named entity 'STAND' named entity 'SPECIFIC' named entity 'ESTABLISHMENT' named entity 'GOALS' named entity 'NATIONAL' named entity 'OPPORTUNITY' named entity 'VACCINE' named entity 'ADVISORY COMMITTEE' named entity 'COMMITTEE' named entity 'REFLECTING' named entity 'PLAY' named entity 'FUTURE' named entity 'CREATED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software